$1,318.00
This Market Spotlight report covers the Primary Sclerosing Cholangitis (PSC) market, comprising key pipeline drugs and upcoming events, clinical trials, probability of success, and a 10-year disease prevalence forecast.
This Market Spotlight report covers the Primary Sclerosing Cholangitis (PSC) market, comprising key pipeline drugs and upcoming events, clinical trials, probability of success, and a 10-year disease prevalence forecast.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
9 EPIDEMIOLOGY
12 PIPELINE DRUGS
16 KEY UPCOMING EVENTS
17 PROBABILITY OF SUCCESS
18 CLINICAL TRIAL LANDSCAPE
19 Sponsors by status
20 Sponsors by phase
21 BIBLIOGRAPHY
22 APPENDIX
LIST OF FIGURES
11 Figure 1: Trends in prevalent cases of PSC, 2019–28
12 Figure 2: Overview of pipeline drugs for PSC in the US
12 Figure 3: Pipeline drugs for PSC, by company
13 Figure 4: Pipeline drugs for PSC, by drug type
13 Figure 5: Pipeline drugs for PSC, by classification
16 Figure 6: Key upcoming events in PSC
17 Figure 7: Probability of success in the autoimmune/immunology-other pipeline
18 Figure 8: Clinical trials in PSC
18 Figure 9: Top 10 drugs for clinical trials in PSC
19 Figure 10: Top 10 companies for clinical trials in PSC
19 Figure 11: Trial locations in PSC
20 Figure 12: PSC trials status
20 Figure 13: PSC trials sponsors, by phase
LIST OF TABLES
10 Table 1: Prevalent cases of PSC, 2019–28
14 Table 2: Pipeline drugs for PSC in the US
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!